SGSM2

Summary

SGSM2 (small G protein signaling modulator 2, HGNC:29026) is a protein-coding gene on chromosome 17p13.3, encoding Small G protein signaling modulator 2 (O43147). Possesses GTPase activator activity towards RAB32, RAB33B and RAB38.

The protein encoded by this gene is a GTPase activator with activity towards RAB32 and RAB33B, which are regulators of membrane trafficking. The encoded protein inactivates RAB32 and can bind RAB9A-GTP, a protein required for RAB32 activation.

Source: NCBI Gene 9905 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 224 total
• MANE Select transcript: NM_014853

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29026
Approved symbol	SGSM2
Name	small G protein signaling modulator 2
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0397
Ensembl gene	ENSG00000141258
Ensembl biotype	protein_coding
OMIM	611418
Entrez	9905

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 11 protein_coding, 5 retained_intron, 2 nonsense_mediated_decay

ENST00000268989, ENST00000426855, ENST00000570431, ENST00000572841, ENST00000572875, ENST00000572925, ENST00000573062, ENST00000573717, ENST00000573851, ENST00000574250, ENST00000574563, ENST00000574650, ENST00000574857, ENST00000575367, ENST00000930413, ENST00000930414, ENST00000968832, ENST00000968833

RefSeq mRNA: 3 — MANE Select: NM_014853 NM_001098509, NM_001346700, NM_014853

CCDS: CCDS32526, CCDS45570, CCDS86557

Canonical transcript exons

ENST00000268989 — 24 exons

Exon	Start	End
ENSE00001593370	2364897	2365057
ENSE00001603745	2372343	2372488
ENSE00001638115	2376733	2376815
ENSE00001641296	2376137	2376261
ENSE00001650836	2373331	2373513
ENSE00001693579	2362838	2362905
ENSE00001694233	2372953	2373081
ENSE00001715393	2375492	2375875
ENSE00001724476	2367271	2367405
ENSE00001774881	2362989	2363134
ENSE00002267698	2337501	2337745
ENSE00003569346	2377857	2377953
ENSE00003601734	2363465	2363599
ENSE00003639699	2365215	2365341
ENSE00003647061	2364059	2364183
ENSE00003655419	2371262	2371415
ENSE00003674914	2379432	2381054
ENSE00003679550	2379036	2379203
ENSE00003680721	2372190	2372254
ENSE00003693491	2376959	2377068
ENSE00003702792	2343545	2343620
ENSE00003703243	2362109	2362270
ENSE00003706615	2364596	2364663
ENSE00003709178	2361637	2361799

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.5141 / max 1398.2321, expressed in 1812 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158808	26.7039	1810
158809	0.4760	265
158816	0.2385	5
158815	0.0400	4
158817	0.0369	6
158810	0.0189	11

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.26	gold quality
cauda epididymis	UBERON:0004360	99.02	gold quality
endothelial cell	CL:0000115	98.92	gold quality
cervix squamous epithelium	UBERON:0006922	98.64	gold quality
pituitary gland	UBERON:0000007	98.60	gold quality
corpus epididymis	UBERON:0004359	98.55	gold quality
adenohypophysis	UBERON:0002196	98.40	gold quality
right frontal lobe	UBERON:0002810	98.24	gold quality
amygdala	UBERON:0001876	98.14	gold quality
nucleus accumbens	UBERON:0001882	98.11	gold quality
cingulate cortex	UBERON:0003027	97.93	gold quality
anterior cingulate cortex	UBERON:0009835	97.91	gold quality
middle temporal gyrus	UBERON:0002771	97.86	gold quality
temporal lobe	UBERON:0001871	97.65	gold quality
primary visual cortex	UBERON:0002436	97.60	gold quality
caudate nucleus	UBERON:0001873	97.59	gold quality
putamen	UBERON:0001874	97.57	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.51	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.29	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.26	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.25	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.23	gold quality
forebrain	UBERON:0001890	97.13	gold quality
ventricular zone	UBERON:0003053	97.13	gold quality
telencephalon	UBERON:0001893	97.11	gold quality
neocortex	UBERON:0001950	97.10	gold quality
lower esophagus mucosa	UBERON:0035834	97.10	gold quality
cerebral cortex	UBERON:0000956	97.09	gold quality
Ammon’s horn	UBERON:0001954	97.01	gold quality
occipital lobe	UBERON:0002021	97.00	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.45
E-GEOD-124858	no	28.62

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting SGSM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-4489	99.50	65.56	785

Literature-anchored findings (GeneRIF, showing 6)

• Identification of novel protein SGSM2 which modulate small G protein (RAP and RAB)-mediated signaling pathway (PMID:17509819)
• RUTBC1 is a Tre2/Bub2/Cdc16 domain-containing protein that binds to Rab9A-GTP both in vitro and in cultured cells, but is not a GTPase-activating protein for Rab9A. (PMID:21808068)
• Data suggest RUTBC1/SGSM2 in melanocytes functions as physiological GTPase-activating protein for Rab32/Rab38 in regulation of transport of melanogenic enzymes (tyrosinase, tyrosinase-related protein 1, dopachrome isomerase) into melanosomes. (PMID:26620560)
• Weighted gene co-expression network analysis identifies specific modules and hub genes related to subsyndromal symptomatic depression. (PMID:30489189)
• Increased expression of SGSM2 is associated with estrogen receptor-positive breast cancer metastasis. (PMID:30744493)
• SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition. (PMID:35264562)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	sgsm2	ENSDARG00000063307
mus_musculus	Sgsm2	ENSMUSG00000038351
rattus_norvegicus	Sgsm2	ENSRNOG00000027194

Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)

Protein

Protein identifiers

Small G protein signaling modulator 2 — O43147 (reviewed: O43147)

Alternative names: RUN and TBC1 domain-containing protein 1

All UniProt accessions (8): B9A6J3, O43147, I3L1Y7, I3L361, I3NI18, J3QSA2, V9GYD2, V9GYJ0

UniProt curated annotations — full annotation on UniProt →

Function. Possesses GTPase activator activity towards RAB32, RAB33B and RAB38. Regulates the trafficking of melanogenic enzymes TYR, TYRP1 and DCT/TYRP2 to melanosomes in melanocytes by inactivating RAB32 and RAB38. Inhibits RAB32 and RAB38 activation both directly by promoting their GTPase activity and indirectly by disrupting the RAB9A-HPS4 interaction which is required for RAB32/38 activation.

Subunit / interactions. Interacts with RAB4A, RAB11A, RAP1A, RAP1B, RAP2A and RAP2B. No interaction with RAB27A. Interacts with RAB9A.

Subcellular location. Cytoplasm. Melanosome.

Tissue specificity. Widely expressed.

Domain organisation. The Rab-GAP TBC domain possesses GTPase activator activity.

Similarity. Belongs to the RUTBC family.

Isoforms (4)

UniProt ID	Names	Canonical?
O43147-1	1	yes
O43147-2	2
O43147-3	3
O43147-5	5

RefSeq proteins (3): NP_001091979, NP_001333629, NP_055668* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000195	Rab-GAP-TBC_dom	Domain
IPR004012	Run_dom	Domain
IPR021935	SGSM1/2_RBD	Domain
IPR035969	Rab-GAP_TBC_sf	Homologous_superfamily
IPR037213	Run_dom_sf	Homologous_superfamily
IPR037745	SGSM1/2	Domain
IPR047345	RUN_SGSM2	Domain

Pfam: PF00566, PF02759, PF12068

UniProt features (24 total): splice variant 6, sequence variant 6, region of interest 3, compositionally biased region 3, domain 2, chain 1, mutagenesis site 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43147-F1	71.97	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 402

Mutagenesis-validated functional residues (1):

Position	Phenotype
803	loss of gtpase activator activity towards rab32, rab33b and rab38.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 127 (showing top): GOZGIT_ESR1_TARGETS_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, GOMF_GTPASE_BINDING, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, WINTER_HYPOXIA_METAGENE, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, GOBP_RETROGRADE_TRANSPORT_ENDOSOME_TO_GOLGI, GOBP_CYTOSOLIC_TRANSPORT, GOCC_PIGMENT_GRANULE, GOBP_GOLGI_VESICLE_TRANSPORT, GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN

GO Biological Process (1): late endosome to Golgi transport (GO:0034499)

GO Molecular Function (2): GTPase activator activity (GO:0005096), small GTPase binding (GO:0031267)

GO Cellular Component (3): cytoplasm (GO:0005737), melanosome (GO:0042470), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
retrograde transport, endosome to Golgi	1
Golgi vesicle transport	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
GTPase binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
pigment granule	1
intracellular vesicle	1

Protein interactions and networks

STRING

914 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SGSM2	SGSM3	Q96HU1	907
SGSM2	RAP1B	P09526	763
SGSM2	RAB4A	P20338	758
SGSM2	RAP2A	P10114	716
SGSM2	RAB11A	P24410	696
SGSM2	RAB9A	P51151	691
SGSM2	RAB3A	P20336	683
SGSM2	RAB8A	P24407	676
SGSM2	RAP1A	P10113	663
SGSM2	RAP2B	P17964	653
SGSM2	RAB5A	P20339	614
SGSM2	RAB32	Q13637	605
SGSM2	ANKRD27	Q96NW4	541
SGSM2	RAB33B	Q9H082	539
SGSM2	TBC1D12	O60347	519

IntAct

24 interactions, top by confidence:

A	B	Type	Score
CETN1	SFI1	psi-mi:“MI:0914”(association)	0.640
PTPRN	SGSM2	psi-mi:“MI:0914”(association)	0.350
PTPRN2	SGSM2	psi-mi:“MI:0914”(association)	0.350
PTPRN	KCNK1	psi-mi:“MI:0914”(association)	0.350
GPC3	PXDNL	psi-mi:“MI:0914”(association)	0.350
DSCR9	SGSM2	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	PTN	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	PNO1	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	MPP1	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	FNBP1L	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	CA12	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	CHD3	psi-mi:“MI:0915”(physical association)	0.000
EGFR	SGSM2	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	GDPD2	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	AFP	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	CELSR3	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	ILF2	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	KHDRBS3	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	RGMA	psi-mi:“MI:0915”(physical association)	0.000
SGSM2	RPS25	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): SGSM2 (Affinity Capture-MS), SGSM2 (Affinity Capture-MS), SGSM2 (Affinity Capture-RNA), SGSM2 (Affinity Capture-MS), SGSM2 (Protein-RNA), RAB2A (Two-hybrid), RAB2B (Two-hybrid), RAB3A (Two-hybrid), RAB3B (Two-hybrid), RAB9A (Two-hybrid), RAB9B (Two-hybrid), SGSM2 (Reconstituted Complex), RAB9A (Affinity Capture-Western), AFP (Two-hybrid), CELSR3 (Two-hybrid)

ESM2 similar proteins: A0A1L8F1M4, A0A8M9QN10, A0JMQ9, A6NIR3, A8DZE6, A8WH69, B2KF05, F1QCY8, O43147, O43900, O54880, P0C6P5, P59729, P97433, Q13009, Q18PD9, Q2NKQ1, Q32L09, Q3U5C7, Q58D79, Q5EB20, Q5PQS0, Q5U464, Q60592, Q6IVY4, Q6P0Q8, Q6ZQF7, Q6ZUJ8, Q71QF9, Q768S4, Q7T2V3, Q7TNN8, Q7TSI1, Q7ZVP1, Q803A0, Q80U12, Q80VL3, Q80Y24, Q8BPQ7, Q8BRB7

Diamond homologs: A1A5B6, O43147, P09379, P48365, Q2NKQ1, Q3MII6, Q6FWI1, Q80U12, Q8BPQ7, Q8BYH7, Q8TBP0, Q8TC07, Q94BY9, Q9CXF4, Q9HA65, Q9UUH7, I2HAA0, Q09830, Q6BU76, Q28CB1, Q8R3D1, Q9NVG8, P48566, Q12344

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

224 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	195
Likely benign	2
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

5683 predictions. Top by Δscore:

Variant	Effect	Δscore
17:2337742:GGAG:G	donor_gain	1.0000
17:2337743:G:GT	donor_gain	1.0000
17:2337745:GGT:G	donor_loss	1.0000
17:2343625:G:GG	donor_gain	1.0000
17:2361798:AGGTG:A	donor_loss	1.0000
17:2361800:G:GC	donor_loss	1.0000
17:2361801:T:G	donor_loss	1.0000
17:2362755:T:TA	acceptor_gain	1.0000
17:2362756:G:A	acceptor_gain	1.0000
17:2362768:ACCT:A	acceptor_gain	1.0000
17:2362836:A:AG	acceptor_gain	1.0000
17:2362837:G:GG	acceptor_gain	1.0000
17:2362837:GCAA:G	acceptor_gain	1.0000
17:2362985:ACAGT:A	acceptor_gain	1.0000
17:2362987:A:AC	acceptor_loss	1.0000
17:2362987:A:AG	acceptor_gain	1.0000
17:2362987:AGT:A	acceptor_gain	1.0000
17:2362987:AGTG:A	acceptor_gain	1.0000
17:2362987:AGTGG:A	acceptor_gain	1.0000
17:2362988:G:GA	acceptor_gain	1.0000
17:2362988:GT:G	acceptor_gain	1.0000
17:2362988:GTG:G	acceptor_gain	1.0000
17:2362988:GTGG:G	acceptor_gain	1.0000
17:2362988:GTGGG:G	acceptor_gain	1.0000
17:2363105:G:GT	donor_gain	1.0000
17:2363131:GGGG:G	donor_gain	1.0000
17:2363132:GGG:G	donor_gain	1.0000
17:2363132:GGGG:G	donor_gain	1.0000
17:2363133:GG:G	donor_gain	1.0000
17:2363133:GGG:G	donor_gain	1.0000

AlphaMissense

6919 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:2343566:G:C	A27P	1.000
17:2377929:T:A	W914R	1.000
17:2377929:T:C	W914R	1.000
17:2343550:G:C	K21N	0.999
17:2343550:G:T	K21N	0.999
17:2343570:T:A	V28D	0.999
17:2361715:T:C	L71P	0.999
17:2362203:T:A	W131R	0.999
17:2362203:T:C	W131R	0.999
17:2362216:C:A	A135E	0.999
17:2362219:T:C	L136P	0.999
17:2362900:T:C	L174P	0.999
17:2362903:T:C	L175P	0.999
17:2362903:T:G	L175R	0.999
17:2362991:G:A	G177R	0.999
17:2362991:G:C	G177R	0.999
17:2362992:G:A	G177E	0.999
17:2362995:C:A	P178H	0.999
17:2362995:C:G	P178R	0.999
17:2363009:T:G	Y183D	0.999
17:2364128:T:A	W293R	0.999
17:2364128:T:C	W293R	0.999
17:2376174:G:C	R796P	0.999
17:2377061:T:C	L887P	0.999
17:2377927:G:C	R913P	0.999
17:2377942:A:T	D918V	0.999
17:2377949:G:C	K920N	0.999
17:2377949:G:T	K920N	0.999
17:2379065:T:A	W932R	0.999
17:2379065:T:C	W932R	0.999

dbSNP variants (sampled 300 via entrez): RS1000034053 (17:2345779 G>A), RS1000084951 (17:2352655 C>T), RS1000147320 (17:2345316 G>C,T), RS1000243493 (17:2345041 C>T), RS1000260080 (17:2361818 C>T), RS1000306546 (17:2349949 G>A), RS1000409510 (17:2357816 C>T), RS1000567866 (17:2363126 G>A), RS1000592795 (17:2360777 C>T), RS1000642310 (17:2348854 T>C), RS1000694422 (17:2349119 C>T), RS1000717104 (17:2367603 G>C), RS1000758641 (17:2353741 G>A,T), RS1000822704 (17:2372358 G>A), RS1000827152 (17:2370602 C>T)

Disease associations

OMIM: gene MIM:611418 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST000442_1	Aortic root size	2.000000e-11
GCST001212_7	Proinsulin levels	3.000000e-09
GCST002539_85	Schizophrenia	3.000000e-10
GCST004521_272	Autism spectrum disorder or schizophrenia	7.000000e-10
GCST007326_28	Number of sexual partners	6.000000e-11
GCST008109_8	Fasting blood proinsulin levels	9.000000e-10
GCST009524_133	Household income (MTAG)	4.000000e-08
GCST009597_178	Multiple sclerosis	2.000000e-06
GCST009863_25	Insulin-related traits (multivariate analysis)	2.000000e-10
GCST010703_278	Brain morphology (MOSTest)	2.000000e-15

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004467	insulin measurement
EFO:0009695	household income
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
sodium arsenite	increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	decreases methylation, increases methylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
bisphenol S	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Catechin	decreases expression, affects cotreatment	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Methapyrilene	increases methylation	1
Smoke	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Toluene	decreases expression, increases methylation	1
Valproic Acid	decreases expression	1
Vitamin E	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Cyclosporine	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer